Meniere's Disease Clinical Trial
— AVERTS-2Official title:
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Verified date | December 2022 |
Source | Otonomy, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
Status | Terminated |
Enrollment | 176 |
Est. completion date | September 15, 2017 |
Est. primary completion date | August 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria includes, but is not limited to: - Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology - Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study lead-in period. - Subject has experienced active vertigo during the lead-in period. - Subject has documented asymmetric sensorineural hearing loss. - Subject agrees to maintain their current treatments for Meniere's disease while on-study. Exclusion Criteria includes, but is not limited to: - Subject is pregnant or lactating. - Subject has a history of immunodeficiency disease. - Subject has a history of previous endolymphatic sac surgery. - Subject has a history of previous use of intratympanic (IT) gentamicin in the affected ear. - Subject has a history of tympanostomy tubes with evidence of perforation or lack of closure. - Subject has experienced an adverse reaction to IT injection of steroids. - Subject has used an investigational drug or device in the 3 months prior to screening. - Subject has previously been randomized to a trial of OTO-104. |
Country | Name | City | State |
---|---|---|---|
United States | Many sites in Europe. Refer to the contact info listed below. | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
Otonomy, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Number of DVD at Week 12 (the 4-week [28 Days] Interval From Week 9 Through Week 12) - FAS-1 Population | In the Full Analysis Set (FAS)-1 population, the number of DVDs at Week 12 (the 4-week [28 days] interval from Week 9 through Week 12) was compared between OTO-104 and placebo. Week 12 = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in. | 3 months | |
Primary | The Number of DVD at Week 12 (the 4-week [28 Days] Interval From Week 9 Through Week 12) - FAS-2 Population | The number of DVDs at Week 12 (the 4-week [28 days] interval from Week 9 through Week 12) was compared between OTO-104 and placebo. Week 12 = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in. | 3 months | |
Secondary | Effect of Vertigo on Daily Activities - Number of Days Sick at Home or Bedridden at Week 12 (Month 3): FAS-1 | Week 12 = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in.
Questionnaire - subjects were instructed to record the effect on their daily activities of their total vertigo experienced that day using a 5-point scoring system: 0 = normal activity = slight limitation = moderate limitation = sick at home = bedridden |
3 months | |
Secondary | Effect of Vertigo on Daily Activities - Number of Days Sick at Home or Bedridden at Week 12 (Month 3): FAS-2 | Week 12 = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in.
Questionnaire - subjects were instructed to record the effect on their daily activities of their total vertigo experienced that day using a 5-point scoring system: 0 = normal activity = slight limitation = moderate limitation = sick at home = bedridden |
3 months | |
Secondary | Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3) | Otoscopic examinations were conducted at each visit. It was considered important to understand if the tympanic perforation that resulted from the IT injection at the Baseline visit persisted at the end of study visit (Week12 [Month 3]). Week 12 = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in. | 3 months | |
Secondary | Audiometry - Shift in Air-Bone Gap at 500 Hz From Baseline to Week 12 (Month 3) | The number of subjects with a change in air-bone gap from Baseline to Week 12 (Month 3) from no impairment (<=10 dB) to impairment (>10 dB) when measure at 500 Hz. Week 12 = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in. | 3 Months | |
Secondary | Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3) | The number of subjects with a change in air-bone gap from Baseline to Week 12 (Month 3) from no impairment at baseline (<= 10 dB) to impairment at Month 3 (>10 dB) when measured at 1000 Hz. Week 12 (Month 3) = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in. | 3 months | |
Secondary | Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3) | The number of subjects with a change in air-bone gap from Baseline to Week 12 (Month 3) from no impairment at baseline (<= 10 dB) to impairment at Month 3 (>10 dB) when measured at 2000 Hz. Week 12 (Month 3) = 12 weeks after dosing at the Baseline visit. The Baseline visit occurred at the end of lead-in. No intervention was administered during lead-in. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06001593 -
Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation
|
Phase 1/Phase 2 | |
Completed |
NCT03325790 -
SPI-1005 for the Treatment of Patients With Meniere's Disease
|
Phase 2 | |
Completed |
NCT02612337 -
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
|
Phase 3 | |
Completed |
NCT02265393 -
A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom
|
Phase 2 | |
Completed |
NCT02309099 -
Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach
|
N/A | |
Completed |
NCT01412177 -
OTO-104 for the Treatment of Meniere's Disease
|
Phase 2 | |
Completed |
NCT01084525 -
OTO-104 for Meniere's Disease
|
Phase 1 | |
Terminated |
NCT02530931 -
Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease
|
Phase 4 | |
Terminated |
NCT02740387 -
Open Label Study of OTO-104 in Subjects With Meniere's Disease
|
Phase 2 | |
Completed |
NCT02158585 -
Study of Lamotrigine to Treat Ménière's Disease
|
Phase 2 | |
Completed |
NCT00145483 -
Sildenafil For Meniere's Disease
|
Phase 4 | |
Suspended |
NCT04026516 -
CAVA: Dizziness Trial
|
N/A | |
Recruiting |
NCT03587701 -
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
|
Phase 2 | |
Completed |
NCT02080312 -
Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent
|
N/A | |
Completed |
NCT01454726 -
Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease
|
Phase 3 | |
Recruiting |
NCT01099046 -
Stress Management Therapy for Meniere's Disease
|
N/A | |
Completed |
NCT00160238 -
Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy
|
Phase 4 | |
Terminated |
NCT02706730 -
A 6-Month Extension Study of OTO-104 in Meniere's Disease
|
Phase 3 | |
Completed |
NCT02718846 -
Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets
|
Phase 4 | |
Completed |
NCT02603081 -
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
|
Phase 1/Phase 2 |